Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management36
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder26
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?24
A review of phase II and III drugs for the treatment and management of endometriosis22
New drugs targeting calcitonin gene-related peptide for the management of migraines19
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia19
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials17
Emerging injectable therapies for osteoarthritis15
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review15
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials14
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?14
Emerging medicines to improve the basic defect in cystic fibrosis13
Emerging biological treatments for asthma12
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape12
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia12
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials11
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms11
A review of emerging factor XI inhibitors10
Emerging drugs for the treatment of herpetic keratitis10
Cannabinoid treatment for the symptoms of autism spectrum disorder10
Emerging tyrosine kinase inhibitors for head and neck cancer9
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?9
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials9
Emerging antiviral therapies and drugs for the treatment of influenza9
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder9
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma9
Early investigational agents for the treatment of rosacea: drugs in phase II and III clinical development9
How will tovorafenib change our treatment of pediatric low-grade glioma?8
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion8
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials7
Correction7
Gene therapy for wet AMD: a paradigm shift in the standard of care7
Emerging drugs for the treatment of irritability associated with autism spectrum disorder7
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis7
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis7
The role of HER2-targeted therapy in urothelial carcinomas7
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma7
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis6
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma6
What can we expect from a combination of datopotamab deruxtecan, carboplatin, and pembrolizumab for brain metastases from non-small cell lung cancer?6
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials6
Emerging drugs in the treatment of chronic cough6
Emerging drugs for the treatment of inflammatory bowel disease6
Correction6
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results6
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?6
Current and emerging drug treatment strategies to tackle sickle cell anemia6
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E5
What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II5
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma5
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma5
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis5
Emerging drugs for the treatment of diabetic nephropathy5
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa5
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond4
Emerging drugs for the treatment of major depressive disorder4
Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers4
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials4
Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update4
Phase II and III trials in systemic sclerosis: from recent FDA approvals to emerging applications of cellular therapies4
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder4
Emerging drugs for the treatment of alopecia areata4
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’4
0.18371796607971